Warning: The NCBI web site requires JavaScript to function. more...
World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria.
Plowe CV, Roper C, Barnwell JW, Happi CT, Joshi HH, Mbacham W, Meshnick SR, Mugittu K, Naidoo I, Price RN, Shafer RW, Sibley CH, Sutherland CJ, Zimmerman PA, Rosenthal PJ.
Malar J. 2007 Sep 6;6:121.
Related citations
The rationale and plan for creating a World Antimalarial Resistance Network (WARN).
Sibley CH, Barnes KI, Plowe CV.
Malar J. 2007 Sep 6;6:118.
World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugs.
Price RN, Dorsey G, Ashley EA, Barnes KI, Baird JK, d'Alessandro U, Guerin PJ, Laufer MK, Naidoo I, Nosten F, Olliaro P, Plowe CV, Ringwald P, Sibley CH, Stepniewska K, White NJ.
Malar J. 2007 Sep 6;6:119.
World Antimalarial Resistance Network (WARN) II: in vitro antimalarial drug susceptibility.
Bacon DJ, Jambou R, Fandeur T, Le Bras J, Wongsrichanalai C, Fukuda MM, Ringwald P, Sibley CH, Kyle DE.
Malar J. 2007 Sep 6;6:120.
World Antimalarial Resistance Network (WARN) IV: clinical pharmacology.
Barnes KI, Lindegardh N, Ogundahunsi O, Olliaro P, Plowe CV, Randrianarivelojosia M, Gbotosho GO, Watkins WM, Sibley CH, White NJ.
Malar J. 2007 Sep 6;6:122.
A network to monitor antimalarial drug resistance: a plan for moving forward.
Sibley CH, Barnes KI, Watkins WM, Plowe CV.
Trends Parasitol. 2008 Jan;24(1):43-8. Epub 2007 Nov 26. Review.
Monitoring and deterring drug-resistant malaria in the era of combination therapy.
Laufer MK, Djimdé AA, Plowe CV.
Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):160-9. Review.
A database of antimalarial drug resistance.
Sibley CH, Ringwald P.
Malar J. 2006 Jun 15;5:48.
Antimalarial drugs: current status and new developments.
Rathore D, McCutchan TF, Sullivan M, Kumar S.
Expert Opin Investig Drugs. 2005 Jul;14(7):871-83. Review.
Controlling malaria: challenges and solutions.
Olliaro P, Taylor WR, Rigal J.
Trop Med Int Health. 2001 Nov;6(11):922-7.
Assessment of safety of the major antimalarial drugs.
Chattopadhyay R, Mahajan B, Kumar S.
Expert Opin Drug Saf. 2007 Sep;6(5):505-21. Review.
Responding to the challenge of antimalarial drug resistance by routine monitoring to update national malaria treatment policies.
Vestergaard LS, Ringwald P.
Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):153-9. Review.
Drug-resistant malaria: molecular mechanisms and implications for public health.
Petersen I, Eastman R, Lanzer M.
FEBS Lett. 2011 Jun 6;585(11):1551-62. Epub 2011 Apr 23. Review.
Spread of anti-malarial drug resistance: mathematical model with implications for ACT drug policies.
Pongtavornpinyo W, Yeung S, Hastings IM, Dondorp AM, Day NP, White NJ.
Malar J. 2008 Nov 2;7:229.
[Molecular markers for malaria drug resistance: necessary but not sufficient criteria to decide change in treatment policy].
Mbacham W, Njikam N.
Med Trop (Mars). 2007 Apr;67(2):183-7. Review. French.
Economic access to effective drugs for falciparum malaria.
Panosian CB.
Clin Infect Dis. 2005 Mar 1;40(5):713-7. Epub 2005 Feb 3.
Drug resistance hampers our capacity to roll back malaria.
Olliaro P.
Clin Infect Dis. 2005 Aug 15;41 Suppl 4:S247-57. Review.
[In vitro susceptibility of P. falciparum isolates from Abidjan (Côte d'Ivoire) to quinine, artesunate and chloroquine].
Touré AO, Koné LP, Jambou R, Konan TD, Demba S, Beugre GE, Koné M.
Sante. 2008 Jan-Mar;18(1):43-7. French.
The prevalence and degree of resistance of Plasmodium falciparum to first-line antimalarial drugs: an in vitro study from a malaria endemic region in Yemen.
Al-Shamahy H, Al-Harazy AH, Harmal NS, Al-Kabsi AM.
Ann Saudi Med. 2007 Nov-Dec;27(6):432-6.
Artemisinin-based combination therapy for treating uncomplicated malaria.
Sinclair D, Zani B, Donegan S, Olliaro P, Garner P.
Cochrane Database Syst Rev. 2009 Jul 8;(3):CD007483. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on